Browse > Article
http://dx.doi.org/10.4166/kjg.2018.72.6.325

Effect of Aprepitant in Patient with Gastroparesis and Related Disorders  

Jung, Kyoungwon (Department of Internal Medicine, Kosin University College of Medicine)
Park, Moo In (Department of Internal Medicine, Kosin University College of Medicine)
Publication Information
The Korean Journal of Gastroenterology / v.72, no.6, 2018 , pp. 325-328 More about this Journal
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pasricha PJ, Yates KP, Sarosiek I, et al. Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders. Gastroenterology 2018;154:65-76.e11.   DOI
2 Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592-1622.   DOI
3 Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut 2014;63:1972-1978.   DOI
4 Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology 2015;149:1762-1774.e4.   DOI
5 Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111 Suppl 8A:106S-112S.   DOI
6 Stapleton J, Wo JM. Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics. Gastrointest Endosc Clin N Am 2009;19:57-72, vi.   DOI
7 Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am 2015;44:97-111.   DOI
8 Lacy BE, Parkman HP, Camilleri M. Chronic nausea and vomiting: evaluation and treatment. Am J Gastroenterol 2018;113:647-659.   DOI
9 Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108:18-37; quiz 38.   DOI
10 Camilleri M. Novel diet, drugs, and gastric interventions for gastroparesis. Clin Gastroenterol Hepatol 2016;14:1072-1080.   DOI
11 Tack J, Camilleri M. New developments in the treatment of gastroparesis and functional dyspepsia. Curr Opin Pharmacol 2018;43:111-117.   DOI
12 Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol 2015;13:1256-1263.e1.   DOI
13 Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998;43:395-400.   DOI
14 Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil 2010;16:407-413.   DOI
15 Sanger GJ, Pasricha PJ. Investigational drug therapies for the treatment of gastroparesis. Expert Opin Investig Drugs 2017;26:331-342.   DOI
16 Carbone F, Rotondo A, Andrews CN, et al. 1077 a controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology 2016;150:S213-S214.
17 Camilleri M, Acosta A. Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil 2015;27:324-332.   DOI
18 Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology 2017;153:1240-1250.e2.   DOI
19 Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J Parenter Enteral Nutr 2003;27:277-281.   DOI
20 Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 2014;722:26-37.   DOI
21 Yokoe T, Hayashida T, Nagayama A, et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Oncologist 2018 Oct 17. [Epub ahead of print]
22 Jacobse J, Mensink H, van der Stoep-Yap MYEC, Kollen WJW, Bresters D, Bredius RGM. Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation. Bone Marrow Transplant 2018;53:1372-1374.   DOI
23 Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J 2016;92:87-98.   DOI
24 Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother 2012;46:e38.
25 Fountoulakis N, Dunn J, Thomas S, Karalliedde J. Successful management of refractory diabetic gastroparesis with long-term aprepitant treatment. Diabet Med 2017;34:1483-1486.   DOI
26 Chong K, Dhatariya K. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. Nat Rev Endocrinol 2009;5:285-288.   DOI